Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Restructuring Costs: 2023-2024

Historic Restructuring Costs for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $29.6 million.

  • Monte Rosa Therapeutics' Restructuring Costs rose 15.01% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year change of. This contributed to the annual value of $29.6 million for FY2024, which is 8.55% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Restructuring Costs stood at $29.6 million, which was up 8.55% from $27.3 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Restructuring Costs registered a high of $29.6 million during FY2024, and its lowest value of $27.3 million during FY2023.
  • For the 2-year period, Monte Rosa Therapeutics' Restructuring Costs averaged around $28.5 million, with its median value being $28.5 million (2023).
  • Data for Monte Rosa Therapeutics' Restructuring Costs shows a peak YoY increased of 8.55% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Monte Rosa Therapeutics' Restructuring Costs stood at $27.3 million in 2023, then climbed by 8.55% to $29.6 million in 2024.